These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Evaluation of effect of empirical attack-preventive immunotherapies in neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis. Ma J; Yu H; Wang H; Zhang X; Feng K J Neuroimmunol; 2022 Feb; 363():577790. PubMed ID: 34959021 [TBL] [Abstract][Full Text] [Related]
44. Utility of aquaporin-4 antibody assay in patients with neuromyelitis optica spectrum disorders. Kim SM; Waters P; Woodhall M; Kim JY; Kim JE; Yang JW; Kim JS; Sung JJ; Park KS; Lee KW Mult Scler; 2013 Jul; 19(8):1060-7. PubMed ID: 23329699 [TBL] [Abstract][Full Text] [Related]
45. Neuromyelitis Optica Spectrum Disorder: Clinical Burden and Cost of Relapses and Disease-Related Care in US Clinical Practice. Royston M; Kielhorn A; Weycker D; Shaff M; Houde L; Tanvir I; Bhattacharyya S; Levy M Neurol Ther; 2021 Dec; 10(2):767-783. PubMed ID: 34046846 [TBL] [Abstract][Full Text] [Related]
46. Peripapillary and parafoveal vascular network assessment by optical coherence tomography angiography in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders. Huang Y; Zhou L; ZhangBao J; Cai T; Wang B; Li X; Wang L; Lu C; Zhao C; Lu J; Quan C; Wang M Br J Ophthalmol; 2019 Jun; 103(6):789-796. PubMed ID: 30021816 [TBL] [Abstract][Full Text] [Related]
47. Prognostic Role of Visual Evoked Potentials in Non-Neuritic Eyes at Multiple Sclerosis Diagnosis. Vecchio D; Barbero P; Galli G; Virgilio E; Naldi P; Comi C; Cantello R J Clin Med; 2023 Mar; 12(6):. PubMed ID: 36983382 [No Abstract] [Full Text] [Related]
48. A comparative optical coherence tomography study in neuromyelitis optica spectrum disorder and multiple sclerosis. Outteryck O; Majed B; Defoort-Dhellemmes S; Vermersch P; Zéphir H Mult Scler; 2015 Dec; 21(14):1781-93. PubMed ID: 25828758 [TBL] [Abstract][Full Text] [Related]
50. The incidence and nature of visual pathway involvement in Friedreich's ataxia. A clinical and visual evoked potential study of 22 patients. Carroll WM; Kriss A; Baraitser M; Barrett G; Halliday AM Brain; 1980 Jun; 103(2):413-34. PubMed ID: 7397485 [TBL] [Abstract][Full Text] [Related]
51. Neuromyelitis optica spectrum disorders in Algeria: A preliminary study in the region of Tizi Ouzou. Daoudi S; Bouzar M Mult Scler Relat Disord; 2016 Mar; 6():37-40. PubMed ID: 27063620 [TBL] [Abstract][Full Text] [Related]
52. [Clinical and epidemiological aspects of neuromyelitis optic spectrum diseases in the russian population]. Simaniv TO; Kochergin IA; Zakharova MN; Korobko DS; Zaslavskii LG; Zelenova OV; Abramov SI Zh Nevrol Psikhiatr Im S S Korsakova; 2021; 121(7):96-103. PubMed ID: 34460164 [TBL] [Abstract][Full Text] [Related]
54. Brain involvement in neuromyelitis optica spectrum disorders. Chan KH; Tse CT; Chung CP; Lee RL; Kwan JS; Ho PW; Ho JW Arch Neurol; 2011 Nov; 68(11):1432-9. PubMed ID: 22084126 [TBL] [Abstract][Full Text] [Related]
55. [Clinical characteristics and follow-up of pediatric patients with neuromyelitis optica and neuromyelitis optica spectrum disorders]. Yun W; Weihua Z; Xiaotun R; Jiuwei L; Xinying Y; Junlan L; Changhong D; Chunhong C; Haitao R; Liying C; Fang F Zhonghua Er Ke Za Zhi; 2015 Apr; 53(4):268-73. PubMed ID: 26182501 [TBL] [Abstract][Full Text] [Related]
56. Optic chiasm measurements may be useful markers of anterior optic pathway degeneration in neuromyelitis optica spectrum disorders. Juenger V; Cooper G; Chien C; Chikermane M; Oertel FC; Zimmermann H; Ruprecht K; Jarius S; Siebert N; Kuchling J; Papadopoulou A; Asseyer S; Bellmann-Strobl J; Paul F; Brandt AU; Scheel M Eur Radiol; 2020 Sep; 30(9):5048-5058. PubMed ID: 32335748 [TBL] [Abstract][Full Text] [Related]
57. Severe structural and functional visual system damage leads to profound loss of vision-related quality of life in patients with neuromyelitis optica spectrum disorders. Schmidt F; Zimmermann H; Mikolajczak J; Oertel FC; Pache F; Weinhold M; Schinzel J; Bellmann-Strobl J; Ruprecht K; Paul F; Brandt AU Mult Scler Relat Disord; 2017 Jan; 11():45-50. PubMed ID: 28104256 [TBL] [Abstract][Full Text] [Related]
58. A prospective case-control study comparing optical coherence tomography characteristics in neuromyelitis optica spectrum disorder- optic neuritis and idiopathic optic neuritis. Zhao X; Qiu W; Zhang Y; Luo Y; Zhang X; Lu L; Yang H BMC Ophthalmol; 2018 Sep; 18(1):247. PubMed ID: 30217177 [TBL] [Abstract][Full Text] [Related]
59. Diagnosis and management of neuromyelitis optica spectrum disorders - An update. Bruscolini A; Sacchetti M; La Cava M; Gharbiya M; Ralli M; Lambiase A; De Virgilio A; Greco A Autoimmun Rev; 2018 Mar; 17(3):195-200. PubMed ID: 29339316 [TBL] [Abstract][Full Text] [Related]
60. Psychiatric comorbidities and suicidality among patients with neuromyelitis optica spectrum disorders in Argentina. Fernández VC; Alonso N; Melamud L; Villa AM Mult Scler Relat Disord; 2018 Jan; 19():40-43. PubMed ID: 29125969 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]